全球皮肤科药物市场（2025-2035 年）

概括

全球皮肤科药物市场正经历强劲成长，这主要得益于皮肤疾病盛行率的上升、未被满足的医疗需求以及对创新治疗方法日益增长的需求。各公司正积极瞄准先前治疗不足的多种疾病，生物製药、生物相似药和新型治疗领域的突破正在再形成市场竞争格局。这些创新透过在银屑病、异位性皮肤炎、脱髮症和皮肤癌等关键治疗领域提供标靶性强、疗效显着的治疗方法，重新定义了标准治疗的概念。

皮肤科药物仍是整个皮肤科市场中支出最大的细分领域，预计到2025年全球整体规模将达到5,28亿美元。这些药物继续发挥重要的治疗作用，涵盖从痤疮等常见皮肤病到银屑病等复杂疾病的治疗。儘管专利到期带来了学名药的竞争，但由于多种候选药物正处于后期临床试验阶段或即将上市，市场前景仍然强劲。

生物製药正成为关键的成长驱动力，为慢性疾病患者和对传统治疗方法无反应的患者提供标靶治疗标靶治疗选择。此外，药物递送系统的创新，特别是先进的局部平台和微针技术，正在提高药物渗透性、耐受性和患者依从性，从而进一步推动市场扩张。

本报告对全球皮肤病药物市场进行了全面分析，包括按地区和细分市场分類的市场规模和预测，以及对皮肤病药物生态系统的详细评估。

涵盖的主题

• 皮肤科药物生态系统
• 市场驱动因素与障碍
• 皮肤疾病、应用领域及主要趋势
• 主要药物分类和主要皮肤科药物分析
• 未来药物开发平臺
• 皮肤科药物传输技术
• 产业蓝图与价值链
• 生态系中 83 家主要企业的概况和策略，包括皮肤病药物研发公司。
• 针对生态系统公司的策略建议
• 市场分析与预测（2025-2035）

范例图：皮肤科在研药物的研发阶段细分

范例图表：全球皮肤科产品支出（按细分市场划分）

预测性分割

治疗类别

• 痤疮和酒糟
• 脱髮症/毛髮疾病
• 皮肤炎
• 银屑病
• 皮肤感染疾病
• 皮肤癌
• 其他疾病

药物输送途径

• 局部的
• 口服
• 注射剂

製药类型

• OTC
• 处方

分销管道

• 医疗机构/诊所
• 零售药房
• 网路药房
• 直接面向消费者（D2C）

药物分类

生物製药

• IL-23
• IL-17
• IL-4/13
• TNF抑制剂
• IL-12/23 及其他

低分子化合物

• 皮质类固醇
• 类视色素
• Calcineurin抑制剂
• PDE4抑制剂
• JAK抑制剂
• 抗感染药物
• 维生素D类似物
• 其他的

基因疗法和新治疗方法

当地市场

• 亚太地区
• 欧洲
• 中东和非洲
• 北美洲
• 拉丁美洲和中美洲

全国市场

• 澳洲
• 巴西
• 加拿大
• 中国
• 埃及
• 法国
• 德国
• 希腊
• 印度
• 以色列
• 义大利
• 日本
• 墨西哥
• 荷兰
• 波兰
• 葡萄牙
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 韩国
• 西班牙
• 瑞士
• 台湾
• 土耳其
• 英国
• 我们

待覆盖公司名单

• 3M
• Abbott Laboratories
• AbbVie
• Abeona Therapeutics
• AbGenomics Holding
• AboundBio
• Absci Corporation
• Aclaris Therapeutics
• Actelion Pharmaceuticals
• Adaptimmune
• AiCuris
• Akouos
• Akros Pharma
• Alfasigma
• Allergan
• Almirall
• AltruBio
• Amgen
• Amplyx Pharmaceuticals
• Amryt Pharma
• Anacor Pharmaceuticals
• AnaptysBio
• AndroScience Corporation
• AnnJi Pharmaceutical
• AOBiome
• ApoPharma
• Apotex
• Arcutis Biotherapeutics
• Arena Pharmaceuticals
• Array BioPharma
• Asana BioSciences
• Astellas Pharma
• AstraZeneca
• Astria Therapeutics
• Autotelic
• Bausch Health Companies
• Bayer Pharmaceuticals
• Bill and Melinda Gates Foundation
• Biocon Biologics
• Biocon Generics
• Biofrontera
• BioGen
• Biomedical Advanced Research and Development Authority（BARDA）
• BioMimetix
• BioOne Capital
• BioRay Pharmaceutical
• Biosintez
• Bio-Thera Solutions
• Boehringer Ingelheim
• Botanix Pharmaceuticals
• BPGbio
• Bristol-Myers Squibb
• Cadila Pharmaceuticals
• Can-Fite BioPharma
• Cantharidin Pharmaceuticals
• Capella BioScience
• Care Capital
• Castle Creek Biosciences
• Celgene
• CellPoint
• Celltrion
• Cerbios-Pharma
• Checkmate Pharmaceuticals
• Chiesi Farmaceutici
• Chugai Pharmaceutical
• Cipher Pharmaceuticals
• CKD Pharmaceuticals
• Clarion Medical Technologies
• Clinuvel Pharmaceuticals
• Coherus BioSciences
• Concert Pharmaceuticals
• CorMedix
• Cosette Pharmaceuticals
• Cosmo Pharmaceuticals
• CSL Behring
• Cumberland Pharmaceuticals
• Cutanea Life Sciences
• Daewoong Pharmaceutical
• Debiopharm
• Dermata Therapeutics
• Dermavant Sciences
• DermBiont
• Dermira
• DFB Soria
• DICE Therapeutics
• Dow Pharmaceutical
• Dr. Reddy's Laboratories
• Durata Therapeutics
• Dusa Pharmaceuticals
• Eirion Therapeutics
• Eli Lilly and Company
• Elorac
• Elsie Biotechnologies
• EMD Serono
• Encore Dermatology
• Escalier Biosciences
• Escient Pharmaceuticals
• European Medicines Agency（EMA）
• Evolus
• Ewopharma
• Exelixis
• Eywa Pharma
• F. Hoffmann-La Roche
• FAES Farma
• FDA
• Fibrocell Science
• G&E Herbal Biotechnology
• Galapagos
• Galderma
• Galectin Therapeutics
• Genentech
• Gilead Sciences
• Glenmark Pharmaceuticals
• GSK（GlaxoSmithKline）
• Gurnet Point
• Gurnet Point Capital
• Hallux
• Hapten Sciences
• Horizon Therapeutics
• Hospira
• Hoth Therapeutics
• Huya Bioscience
• Ichnos Glenmark Innovation
• Ichnos Sciences
• Immunocore
• Immutep
• Incyte Corporation
• Innovation Pharmaceuticals
• InSite Vision
• Iovance Biotherapeutics
• Ipsen
• Janssen Pharmaceutical
• Janssen Research & Development
• Japan Tobacco
• Jiangsu Hengrui Medicine
• Johnson & Johnson
• Journey Medical Corporation
• Kiniksa Pharmaceuticals
• Kintara Therapeutics
• Krystal Biotech
• Kyowa Kirin
• Ladrome
• LEO Pharma
• Libertas Bio
• Ligand Pharmaceuticals
• Lipidor
• Maruho
• Mayne Pharma
• MB Venture Partners
• Meda Pharma
• Melinta Therapeutics
• Merck & Co
• Merck KGaA
• Merz Pharma
• Microsoft
• Moderna
• MorphoSys
• Mycovia Pharmaceuticals
• Mylan
• Nanology
• Nestle Skin Health
• Neumedicines
• Nielsen BioSciences
• Novartis
• Novo Holdings
• Oncolys Biopharma
• Oncotelic
• Ono Pharmaceutical
• Optinose
• OriCiro Genomics
• Ortho Dermatologics
• Paratek Pharmaceuticals
• Pelthos Therapeutics
• Pfizer
• Philogen
• Phio Pharmaceuticals
• Photogen Technologies
• Pierre Fabre
• Pierre Fabre Laboratories
• Poli Group
• Polpharma Biologics
• PolyMedix
• Precigen
• Prevail Therapeutics
• Principia Biopharma
• Priovant Therapeutics
• Promius Pharma
• ProQR Therapeutics
• Proteologix
• Protomer Technologies
• Provectus Biopharmaceuticals
• Pyxis Oncology
• Qurient
• Ralexar Therapeutics
• Ranbaxy Laboratories
• Rani Therapeutics
• Regeneron Pharmaceuticals
• Roche
• Roivant Sciences
• Samsung
• Samsung Bioepis
• Sandoz AG
• Sanofi
• SBI Biotech
• Searchlight Pharma
• Seattle Genetics
• Sierra Oncology
• Sinclair Pharma
• Sol-Gel Technologies
• Soligenix
• Stiefel Laboratories
• Sun Pharmaceutical Industries
• Takeda
• Takeda Oncology
• Taro Pharmaceutical Industries
• Teva Pharmaceutical Industries
• The Proactiv Company
• Timber Pharmaceuticals
• Tioga Pharmaceuticals
• Torii Pharmaceutical
• Trillium Therapeutics
• UCB Biopharma
• UNION Therapeutics
• University of Pennsylvania
• Upjohn
• URL Pharma
• US WorldMeds
• Valeant Pharmaceuticals
• Vanda Pharmaceuticals
• Vectans Pharma
• Verrica Pharmaceuticals
• VidacPharma
• Villaris Therapeutics
• Vyne Therapeutics
• Zydus Group

Synopsis:

The global dermatological drugs market is experiencing robust growth, driven by rising prevalence of skin disorders, persistent unmet medical needs, and increased demand for innovative therapies. Companies are strategically targeting diverse and previously underserved conditions, with breakthroughs across biologics, biosimilars, and novel therapeutic classes reshaping the competitive landscape. These innovations are delivering highly targeted, high-efficacy treatments across major therapeutic areas, including psoriasis, atopic dermatitis, alopecia areata, and skin cancer, and redefining standards of care.

Dermatological drugs remain the largest segment of spending within the broader dermatology market, projected to reach $52.8 billion globally by 2025. They continue to serve as the primary treatment option for both common conditions, such as acne, and complex diseases, including psoriasis. While patent expirations have introduced generic competition, the market outlook remains robust, supported by several late-stage and near-market drug candidates.

Biologics have emerged as a key growth driver, offering targeted treatment options for chronic conditions and providing targeted options for patients unresponsive to traditional therapies. Complementing this, innovations in drug delivery systems, particularly advanced topical platforms and microneedle technologies, are improving penetration, tolerability, and patient adherence, further supporting market expansion.

The "Dermatological Drugs Market: 2025 - 2035 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.

The report covers market sizing & forecasts from 2025 - 2035 period which are segmented across seven therapeutic categories, three routes of administration, two drug types (OTC vs. Prescription), four distribution channels, three major drug classes (biologics, small molecules, gene & emerging therapies), and 26 leading countries across five regions.

Topics Covered:

The report covers the following topics:

• Dermatological drugs ecosystem
• Market drivers and barriers
• Dermatological disorders, application areas and key trends
• Analysis of key drug classes and leading dermatological drugs
• Future drug development pipeline
• Dermatological drug delivery technologies
• Industry roadmap and value chain
• Profiles and strategies of 83 leading ecosystem players, including dermatological drug developers
• Strategic recommendations for ecosystem players
• Market analysis and forecasts from 2025 till 2035

Sample Figure: Distribution of Dermatological Pipeline Candidates by Developmental Phase (%)

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset, profiling 216 drug candidates.

Key Findings:

The report has the following key findings.

• Global dermatological drug spending is projected to reach approximately $52.8 billion in 2025, driven by sustained demand across inflammatory and chronic skin diseases.
• Advanced biologics remain the primary growth engine, supported by high-impact approvals and label expansions across atopic dermatitis, urticaria, prurigo nodularis, and psoriasis.
• IL-23 inhibitors (risankizumab, guselkumab) and dual-pathway IL-17 agents (bimekizumab) are setting the new standard for long-term, durable control of moderate-to-severe disease, reflecting the market's move toward deep, cytokine-specific immunology.
• TYK2 inhibitors, led by deucravacitinib, are reshaping competitive dynamics by offering targeted efficacy with the convenience of oral dosing, positioning them as credible alternatives to injectables.
• Innovation in topical agents such as JAK-based creams and PDE4 inhibitors continues to strengthen, improving localized therapeutic control and expanding treatment options for chronic inflammatory conditions.
• The 2025 commercial entry of multiple ustekinumab biosimilars marks a structural shift in pricing and access, prompting originators to deploy aggressive lifecycle and payer-defense strategies.
• Strategic acquisitions and alliances remain central to growth. Notable examples include J&J's acquisition of Proteologix, adding two bispecific antibodies for atopic dermatitis and reinforcing the industry-wide pivot toward precision immunology.

Key Questions Answered:

The report provides answers to the following key questions.

• How big is the dermatological drugs opportunity?
• What trends, challenges and barriers are influencing its growth?
• How is the ecosystem evolving by segment and region?
• What will the market size be in 2025 and at what rate will it grow?
• Which countries and submarkets will see the highest percentage of growth?
• What are the prospects of biosimilar drugs in dermatology?
• What are the key drug delivery technologies being used in dermatological treatments?
• How big is the market for psoriasis drugs?
• Who are the key market players and what are their strategies?
• How will patent expirations of innovator drugs impact the market?
• What strategies should dermatological drug manufacturers adopt to remain competitive?

Sample Figure: Global Dermatology Product Spending by Submarket (%)

Forecast Segmentation:

The report provides detailed forecasts across multiple dimensions of the dermatological drugs market, including:

Therapeutic Category

• Acne & Rosacea
• Alopecia & Hair Disorders
• Dermatitis
• Psoriasis
• Skin Infections
• Skin Cancer
• Other Conditions

Drug Delivery Route

• Topical
• Oral
• Parenteral Formulations

Drug Type

• Over-the-Counter (OTC)
• Prescription

Distribution Channel

• Point-of-Care/Clinic
• Retail Pharmacies
• Digital Pharmacies
• Direct-to-Consumer (D2C)

• Drug Class

Biologics

• IL-23
• IL-17
• IL-4/13
• TNF inhibitors
• IL-12/23 & Others

Small Molecules

• Corticosteroids
• Retinoids
• Calcineurin inhibitors
• PDE4 inhibitors
• JAK inhibitors
• Anti-infectives
• Vitamin D analogues
• Others

Gene & Emerging Therapies

Regional Markets

• Asia Pacific
• Europe
• Middle East & Africa
• North America
• Latin & Central America

Country Markets

• Australia
• Brazil
• Canada
• China
• Egypt
• France
• Germany
• Greece
• India
• Israel
• Italy
• Japan
• Mexico
• Netherlands
• Poland
• Portugal
• Russia
• Saudi Arabia
• South Africa
• South Korea
• Spain
• Switzerland
• Taiwan
• Turkey
• UK
• USA

List of Companies Mentioned:

The following companies and organizations have been reviewed, discussed or mentioned in the report.

• 3M
• Abbott Laboratories
• AbbVie
• Abeona Therapeutics
• AbGenomics Holding
• AboundBio
• Absci Corporation
• Aclaris Therapeutics
• Actelion Pharmaceuticals
• Adaptimmune
• AiCuris
• Akouos
• Akros Pharma
• Alfasigma
• Allergan
• Almirall
• AltruBio
• Amgen
• Amplyx Pharmaceuticals
• Amryt Pharma
• Anacor Pharmaceuticals
• AnaptysBio
• AndroScience Corporation
• AnnJi Pharmaceutical
• AOBiome
• ApoPharma
• Apotex
• Arcutis Biotherapeutics
• Arena Pharmaceuticals
• Array BioPharma
• Asana BioSciences
• Astellas Pharma
• AstraZeneca
• Astria Therapeutics
• Autotelic
• Bausch Health Companies
• Bayer Pharmaceuticals
• Bill and Melinda Gates Foundation
• Biocon Biologics
• Biocon Generics
• Biofrontera
• BioGen
• Biomedical Advanced Research and Development Authority (BARDA)
• BioMimetix
• BioOne Capital
• BioRay Pharmaceutical
• Biosintez
• Bio-Thera Solutions
• Boehringer Ingelheim
• Botanix Pharmaceuticals
• BPGbio
• Bristol-Myers Squibb
• Cadila Pharmaceuticals
• Can-Fite BioPharma
• Cantharidin Pharmaceuticals
• Capella BioScience
• Care Capital
• Castle Creek Biosciences
• Celgene
• CellPoint
• Celltrion
• Cerbios-Pharma
• Checkmate Pharmaceuticals
• Chiesi Farmaceutici
• Chugai Pharmaceutical
• Cipher Pharmaceuticals
• CKD Pharmaceuticals
• Clarion Medical Technologies
• Clinuvel Pharmaceuticals
• Coherus BioSciences
• Concert Pharmaceuticals
• CorMedix
• Cosette Pharmaceuticals
• Cosmo Pharmaceuticals
• CSL Behring
• Cumberland Pharmaceuticals
• Cutanea Life Sciences
• Daewoong Pharmaceutical
• Debiopharm
• Dermata Therapeutics
• Dermavant Sciences
• DermBiont
• Dermira
• DFB Soria
• DICE Therapeutics
• Dow Pharmaceutical
• Dr. Reddy's Laboratories
• Durata Therapeutics
• Dusa Pharmaceuticals
• Eirion Therapeutics
• Eli Lilly and Company
• Elorac
• Elsie Biotechnologies
• EMD Serono
• Encore Dermatology
• Escalier Biosciences
• Escient Pharmaceuticals
• European Medicines Agency (EMA)
• Evolus
• Ewopharma
• Exelixis
• Eywa Pharma
• F. Hoffmann-La Roche
• FAES Farma
• FDA
• Fibrocell Science
• G&E Herbal Biotechnology
• Galapagos
• Galderma
• Galectin Therapeutics
• Genentech
• Gilead Sciences
• Glenmark Pharmaceuticals
• GSK (GlaxoSmithKline)
• Gurnet Point
• Gurnet Point Capital
• Hallux
• Hapten Sciences
• Horizon Therapeutics
• Hospira
• Hoth Therapeutics
• Huya Bioscience
• Ichnos Glenmark Innovation
• Ichnos Sciences
• Immunocore
• Immutep
• Incyte Corporation
• Innovation Pharmaceuticals
• InSite Vision
• Iovance Biotherapeutics
• Ipsen
• Janssen Pharmaceutical
• Janssen Research & Development
• Japan Tobacco
• Jiangsu Hengrui Medicine
• Johnson & Johnson
• Journey Medical Corporation
• Kiniksa Pharmaceuticals
• Kintara Therapeutics
• Krystal Biotech
• Kyowa Kirin
• Ladrome
• LEO Pharma
• Libertas Bio
• Ligand Pharmaceuticals
• Lipidor
• Maruho
• Mayne Pharma
• MB Venture Partners
• Meda Pharma
• Melinta Therapeutics
• Merck & Co
• Merck KGaA
• Merz Pharma
• Microsoft
• Moderna
• MorphoSys
• Mycovia Pharmaceuticals
• Mylan
• Nanology
• Nestle Skin Health
• Neumedicines
• Nielsen BioSciences
• Novartis
• Novo Holdings
• Oncolys Biopharma
• Oncotelic
• Ono Pharmaceutical
• Optinose
• OriCiro Genomics
• Ortho Dermatologics
• Paratek Pharmaceuticals
• Pelthos Therapeutics
• Pfizer
• Philogen
• Phio Pharmaceuticals
• Photogen Technologies
• Pierre Fabre
• Pierre Fabre Laboratories
• Poli Group
• Polpharma Biologics
• PolyMedix
• Precigen
• Prevail Therapeutics
• Principia Biopharma
• Priovant Therapeutics
• Promius Pharma
• ProQR Therapeutics
• Proteologix
• Protomer Technologies
• Provectus Biopharmaceuticals
• Pyxis Oncology
• Qurient
• Ralexar Therapeutics
• Ranbaxy Laboratories
• Rani Therapeutics
• Regeneron Pharmaceuticals
• Roche
• Roivant Sciences
• Samsung
• Samsung Bioepis
• Sandoz AG
• Sanofi
• SBI Biotech
• Searchlight Pharma
• Seattle Genetics
• Sierra Oncology
• Sinclair Pharma
• Sol-Gel Technologies
• Soligenix
• Stiefel Laboratories
• Sun Pharmaceutical Industries
• Takeda
• Takeda Oncology
• Taro Pharmaceutical Industries
• Teva Pharmaceutical Industries
• The Proactiv Company
• Timber Pharmaceuticals
• Tioga Pharmaceuticals
• Torii Pharmaceutical
• Trillium Therapeutics
• UCB Biopharma
• UNION Therapeutics
• University of Pennsylvania
• Upjohn
• URL Pharma
• US WorldMeds
• Valeant Pharmaceuticals
• Vanda Pharmaceuticals
• Vectans Pharma
• Verrica Pharmaceuticals
• VidacPharma
• Villaris Therapeutics
• Vyne Therapeutics
• Zydus Group